Data Sheet (Cat.No.T11264)

FAPI-4

Chemical Properties



CAS No. : 2374782-02-0

Formula: C40H54F2N10O10

Molecular Weight: 872.92

Storage: Keep away from direct sunlight,Store at low temperature
Store at -20°C
Actual storage temperature shall be subject to the COA.

Biological Description

Description	FAPI-4 FAPI-4 is a fibroblast activating protein (FAP) inhibitor, a FAPI ligand, which shows strong liver uptake in PET imaging of primary liver cancer hepatocellular carcinoma (HCC) and is commonly used in PET imaging for the study of cancer.
Targets(IC50)	Others,Immunology/Inflammation related
In vivo	In 8-week-old BALB/c nu/nu mice inoculated with HT-1080-FAP cells, FAPI-4 (30 nmol per mouse; intravenous injection; once) revealed high overall tumor uptake[2].

Solubility Information

Solubility	DMSO: 80 mg/mL (91.65 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (3.78 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1456 mL	5.7279 mL	11.4558 mL
5 mM	0.2291 mL	1.1456 mL	2.2912 mL
10 mM	0.1146 mL	0.5728 mL	1.1456 mL
50 mM	0.0229 mL	0.1146 mL	0.2291 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Giesel FL, et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392.
Anastasia Loktev, et al. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. J Nucl Med. 2019 Oct;60(10):1421-1429.